NCT07224672 2026-03-17
ALANIS
GlaxoSmithKline
Phase 2 Not yet recruiting
Clinical Trials
26 trialsNCT07477587 2026-03-17
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
Shanghai Henlius Biotech
Phase 1 Not yet recruiting
NCT07393282 2026-03-16
LINKER-SMM2
Regeneron Pharmaceuticals
Phase 3 Not yet recruiting
NCT07454187 2026-03-06
To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07336472 2026-02-25
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Fortvita Biologics (USA)Inc.
Phase 1/2 Not yet recruiting
NCT07428369 2026-02-23
LINKER-MM8
Regeneron Pharmaceuticals
Phase 2/3 Not yet recruiting
NCT07421856 2026-02-19
Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.
Hebei Senlang Biotechnology Inc., Ltd.
Phase 1/2 Not yet recruiting
NCT07391761 2026-02-18
A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan
Pfizer
Not yet recruiting
NCT07409246 2026-02-13
A Study to Evaluate the, Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
AbbVie
Phase 1 Not yet recruiting
NCT07400744 2026-02-10
A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects
Qilu Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT07354555 2026-01-21
MMExFFPE
BIWAKO
Not yet recruiting
NCT07255898 2025-12-01
A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT07227311 2025-11-12
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
GlaxoSmithKline
Phase 2 Not yet recruiting
NCT07107204 2025-09-17
A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies
Biotroy Therapeutics
Phase 1/2 Not yet recruiting
NCT07090954 2025-07-29
A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07055724 2025-07-09
Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis
Nanjing IASO Biotechnology Co., Ltd.
Phase 2 Not yet recruiting
NCT06825845 2025-02-13
Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy
CARsgen Therapeutics Co., Ltd.
Not yet recruiting
NCT06742138 2024-12-19
To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT06705725 2024-11-26
Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma
Carbiogene Therapeutics Co. Ltd.
Phase 1 Not yet recruiting
NCT06323447 2024-10-09
PC002
Leuko Labs, Inc.
Not yet recruiting
NCT06500507 2024-07-15
A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT05545202 2024-04-03
A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation
Pharmacosmos A/S
Phase 4 Not yet recruiting
NCT06333509 2024-03-27
Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL
CARsgen Therapeutics Co., Ltd.
Phase 1/2 Not yet recruiting
NCT05860179 2023-05-23
Examination of Trends in Multiple Myeloma Trial Patient Experiences
Power Life Sciences Inc.
Not yet recruiting
NCT05181501 2022-01-06
A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)
Nanjing IASO Biotechnology Co., Ltd.
Phase 1 Not yet recruiting
NCT05055791 2021-09-24
A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1/2 Not yet recruiting